Aa retrospective study of comparative effectiveness and safety of rivaroxaban and warfarin among Nonvalvular Atrial Fibrillation (NVAF) patients with obesity and polypharmacy in the USA
Latest Information Update: 07 Feb 2022
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Cardiovascular disorders; Stroke; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 29 Jan 2022 Results published in the American Journal of Cardiovascular Drugs
- 31 May 2021 New trial record
- 25 May 2021 Results published in the Advances in Therapy